• 1
    Weiner HL, Mackin GA, Matsui M, Orav EJ, Khoury SJ, Dawson DM, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259: 13214.
  • 2
    Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993; 261: 172730.
  • 3
    Nussenblatt RB, Caspi RR, Mahdi R, Chan CC, Roberge F, Lider O, et al. Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. J Immunol 1990; 144: 168995.
  • 4
    Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A 1991; 88: 102526.
  • 5
    Sun JB, Holmgren J, Czerkinsky C. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci U S A 1994; 91: 107959.
  • 6
    Strobel S, Mowat AM. Immune responses to dietary antigens: oral tolerance. Immunol Today 1998; 19: 17381.
  • 7
    Couvreur P, Kante B, Roland M, Speiser P. Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum. J Pharm Sci 1979; 68: 15214.
  • 8
    Illum L, Davis SS, Muller RH, Mak E, West P. The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer—poloxamine 908. Life Sci 1987; 40: 36774.
  • 9
    Maincent P, Le Verge R, Sado P, Couvreur P, Devissaguet JP. Disposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles. J Pharm Sci 1986; 75: 9558.
  • 10
    Desai MP, Labhasetwar V, Amidon GL, Levy RJ. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 1996; 13: 183845.
  • 11
    Urata T, Arimori K, Nakano H. Modification of release rates of cyclosporin A from polyl(L-lactic acid) microspheres by fatty acid esters and in-vivo evaluation of the microspheres. J Control Release 1999; 58: 13341.
  • 12
    Rosa GD, Iommelli R, La Rotonda MI, Miro A, Quaglia F. Influence of the co-encapsulation of different non-ionic surfactants on the properties of PLGA insulin-loaded microspheres. J Control Release 2000; 69: 28395.
  • 13
    Okada H, Heya T, Ogawa Y, Shimamoto T. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats. J Pharmacol Exp Ther 1988; 244: 74450.
  • 14
    Denis-Mize KS, Dupuis M, MacKichan ML, Singh M, Doe B, O'Hagan D, et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther 2000; 7: 210512.
  • 15
    Teitelbaum D, Arnon R, Sela M. Immunomodulation of experimental autoimmune encephalitis by oral administration of copolymer 1. Proc Natl Acad Sci U S A 1999; 96: 38427.
  • 16
    Fridkis-Hareli M, Rosloniec EF, Fugger L, Strominger JL. Synthetic amino acid copolymers that bind to HLA-DR proteins and inhibit type II collagen-reactive T cell clones. Proc Natl Acad Sci U S A 1998; 95: 1252831.
  • 17
    Ito HO, So T, Ueda T, Imoto T, Koga T. Prevention of collagen induced arthritis (CIA) by treatment with polyethylene glycol-conjugated type II collagen: distinct tolerogenic property of the conjugated collagen from the native one. Clin Exp Immunol 1997; 108: 2139.
  • 18
    Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977; 146: 85768.
  • 19
    Stuart JM, Cremer MA, Townes AS, Kang AH. Type II collagen induced arthritis in rats: passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J Exp Med 1982; 155: 116.
  • 20
    Sieper J, Kary S, Sörensen H, Alten R, Eggens U, Hüge W, et al. Oral type II collagen treatment in early rheumatoid arthritis: a double-blind, placebo-controlled, randomized trial. Arthritis Rheum 1996; 39: 4151.
  • 21
    McKown KM, Carbone LD, Kaplan SB, Aelion JA, Lohr KM, Cremer MA, et al. Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum 1999; 42: 12048.
  • 22
    Stuart JM, Cremer MA, Kang AH, Townes AS. Collagen-induced arthritis in rats: evaluation of early immunologic events. Arthritis Rheum 1979; 22: 134451.
  • 23
    Stuart JM, Townes AS, Kang AH. Nature and specificity of the immune response to collagen in type II collagen-induced arthritis in mice. J Clin Invest 1982; 69: 67383.
  • 24
    Wooley PH, Luthra HS, Stuart JM, David CS. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med 1981; 154: 688700.
  • 25
    Chen Y, Inobe J, Marks R, Gonnella P, Kuchroo VK, Weiner HL. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995; 376: 17780.
  • 26
    Whitacre CC, Gienapp IE, Orosz CG, Bitar DM. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J Immunol 1991; 147: 215563.
  • 27
    Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of TGF-β, interleukin 4, and PGE in the brain. J Exp Med 1992; 176: 135564.
  • 28
    Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265: 123740.
  • 29
    Ermak TH, Dougherty EP, Bhagat HR, Kabok Z, Pappo J. Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer's patch M cells. Cell Tissue Res 1995; 279: 4336.
  • 30
    Smith MW, Thomas NW, Kenkins PG, Miller NG, Cremashin D, Porta C. Selective transport of microparticles across Peyer's patch follicle-associated M cells from mice and rats. Exp Physiol 1995; 80: 73543.
  • 31
    Jepson MA, Clark MA, Foster N, Mason CM, Bennett MK, Simmons NL, et al. Targeting to intestinal M cells. J Anat 1996; 189: 50716.
  • 32
    Torche AM, Jouan H, Le Corre P, Albina E, Primault R, Jestin A, et al. Ex vivo and in situ PLGA microspheres uptake by pig ileal Peyer's patch segment. Int J Pharm 2000; 201: 1527.
  • 33
    Viney JL, Mowat AM, O'Malley JM, Williamson E, Fanger NA. Expanding dendritic cells in vivo enhances the induction of oral tolerance. J Immunol 1998; 160: 581525.
  • 34
    Iwasaki A, Kelsall BL. Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J Exp Med 1999; 190: 22939.
  • 35
    Conway MA, Madrigal-Estebas L, McClean S, Brayden DJ, Mills KH. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells. Vaccine 2001; 19: 194050.
  • 36
    Pecquet S, Leo E, Fritsche R, Pfeifer A, Couvreur P, Fattal E. Oral tolerance elicited in mice by beta-lactoglobulin entrapped in biodegradable microspheres. Vaccine 2000; 18: 1196202.
  • 37
    Seki N, Sudo Y, Yoshioka T, Sugihara S, Fujitsu T, Sakuma S, et al. Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cell-mediated immunity. J Immunol 1988; 140: 147784.
  • 38
    Kim W-U, Yoo W-H, Park W, Kang Y-M, Kim S-I, Park J-H, et al. IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis. J Rheumatol 2000; 27: 57581.
  • 39
    Kim H-Y, Kim W-U, Cho M-L, Lee SK, Youn J, Kim S-I, et al. Enhanced T cell proliferative response to type II collagen and synthetic peptide CII (255–274) in patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 208593.
  • 40
    Park S-H, Min D-J, Cho M-L, Kim W-U, Youn J, Park W, et al. Shift toward T helper 1 cytokines by type II collagen–reactive T cells in patients with rheumatoid arthritis. Arthritis Rheum 2001; 44: 5619.
  • 41
    Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 1992; 89: 73759.
  • 42
    Thorbecke GJ, Schwarcz R, Leu J, Huang C, Simmons WJ. Modulation by cytokines of induction of oral tolerance to type II collagen. Arthritis Rheum 1999; 42: 1108.
  • 43
    Fujihashi K, Dohi T, Rennert PD, Yamamoto M, Koga T, Kiyono H, et al. Peyer's patches are required for oral tolerance to proteins. Proc Natl Acad Sci U S A 2001; 98: 33105.